Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...